Test Id : BNZU
Benzodiazepines Confirmation, Random, Urine
Useful For
Suggests clinical disorders or settings where the test may be helpful
Detecting drug use involving benzodiazepines such as alprazolam, chlordiazepoxide, clonazepam, diazepam, midazolam, oxazepam, temazepam, clobazam, flunitrazepam, flurazepam, lorazepam, prazepam, triazolam, and zolpidem
Method Name
A short description of the method used to perform the test
Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)
NY State Available
Indicates the status of NY State approval and if the test is orderable for NY State clients.
Reporting Name
Lists a shorter or abbreviated version of the Published Name for a test
Aliases
Lists additional common names for a test, as an aid in searching
7-Amino Flunitrazepam (Metabolite of Flunitrazepam) (Rohypnol)
7-Aminoclonazepam
Alprazolam (Xanax)
Ativan (Lorazepam)
Benzodiazepines
Chlordiazepoxide (Librium)
Clonazepam
Dalmane (Flurazepam)
Diazepam (Valium)
Flunitrazepam (Rohypnol)
Flurazepam (Dalmane)
Halcion (Triazolam)
Hydroxy-Ethyl Flurazepam (Metabolite of Flurazepam)
Librium (Chlordiazepoxide)
Lorazepam (Ativan)
Oxazepam (Serax)
Restoril (Temazepam)
Rohypnol (Flunitrazepam)
Serax (Oxazepam)
Temazepam (Restoril)
Triazolam (Halcion)
Valium (Diazepam)
Xanax (Alprazolam)
Specimen Type
Describes the specimen type validated for testing
Urine
Ordering Guidance
For situations where chain of custody is required, a Chain-of-Custody Kit (T282) is available. For chain-of-custody testing, order BNZX / Benzodiazepines Confirmation, Chain of Custody, Random, Urine.
Additional drug panels and specific requests are available. Call 800-533-1710 or 507-266-5700.
Additional Testing Requirements
If urine creatinine is required or adulteration of the sample is suspected, also order ADULT / Adulterants Survey, Random, Urine in addition to this test.
Specimen Required
Defines the optimal specimen required to perform the test and the preferred volume to complete testing
Supplies: Sarstedt Aliquot Tube, 5 mL (T914)
Collection Container/Tube: Plastic urine container
Submission Container/Tube: Plastic, 5-mL tube
Specimen Volume: 1 mL
Collection Instructions:
1. Collect a random urine specimen.
2. No preservative
Additional Information:
1. No specimen substitutions.
2. STAT requests are not accepted for this test.
3. Submitting less than 1 mL will compromise our ability to perform all necessary testing.
Forms
If not ordering electronically, complete, print, and send a Therapeutics Test Request (T831) with the specimen.
Specimen Minimum Volume
Defines the amount of sample necessary to provide a clinically relevant result as determined by the testing laboratory. The minimum volume is sufficient for one attempt at testing.
1 mL
Reject Due To
Identifies specimen types and conditions that may cause the specimen to be rejected
Gross hemolysis | Reject |
Icterus | Reject |
Specimen Stability Information
Provides a description of the temperatures required to transport a specimen to the performing laboratory, alternate acceptable temperatures are also included
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Urine | Refrigerated (preferred) | 7 days | |
Frozen | 14 days |
Useful For
Suggests clinical disorders or settings where the test may be helpful
Detecting drug use involving benzodiazepines such as alprazolam, chlordiazepoxide, clonazepam, diazepam, midazolam, oxazepam, temazepam, clobazam, flunitrazepam, flurazepam, lorazepam, prazepam, triazolam, and zolpidem
Clinical Information
Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test
Benzodiazepines are any of a group of compounds having a common molecular structure and acting similarly as depressants of the central nervous system. As a class of drugs, benzodiazepines are among the drugs most frequently prescribed in the western hemisphere because of their efficacy, safety, low addiction potential, minimal side effects, and high public demand for sedative and anxiolytic agents.
Reference Values
Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.
Negative (Positive results are reported with a quantitative result.)
Cutoff concentrations by liquid chromatography tandem mass spectrometry:
Alprazolam: 10 ng/mL
Alpha-hydroxyalprazolam: 10 ng/mL
Chlordiazepoxide: 10 ng/mL
Clonazepam: 10 ng/mL
7-Aminoclonazepam: 10 ng/mL
Diazepam: 10 ng/mL
Nordiazepam: 10 ng/mL
Midazolam: 10 ng/mL
Alpha-hydroxy midazolam: 10 ng/mL
Oxazepam: 10 ng/mL
Temazepam: 10 ng/mL
Clobazam: 10 ng/mL
N-Desmethylclobazam: 10 ng/mL
Flunitrazepam: 10 ng/mL
7-Aminoflunitrazepam: 10 ng/mL
Flurazepam: 10 ng/mL
2-Hydroxy ethyl flurazepam: 10 ng/mL
Lorazepam: 10 ng/mL
Prazepam: 10 ng/mL
Triazolam: 10 ng/mL
Alpha-hydroxy triazolam: 10 ng/mL
Zolpidem: 10 ng/mL
Zolpidem phenyl-4-carboxylic acid: 10 ng/mL
Interpretation
Provides information to assist in interpretation of the test results
Benzodiazepines are extensively metabolized, and the parent compounds are not detected in urine. This test screens for (and confirms) the presence of:
-Alprazolam
-Alpha-hydroxyalprazolam (metabolite of alprazolam)
-Chlordiazepoxide
-Clonazepam
-7-Aminoclonazepam (metabolite of clonazepam)
-Diazepam (separate prescribable drug and metabolite of medzazepam)
-Nordiazepam (metabolite of clorazepate, halazepam, prazepam, diazepam and medazepam)
-Midazolam
-Alpha-hydroxy midazolam (metabolite of midazolam)
-Oxazepam (separate prescribable drug and metabolite of clorazepate, halazepam, prazepam, medazepam, temazepam, and diazepam)
-Temazepam (separate prescribable drug and metabolite of medazepam and diazepam)
-Clobazam
-N-Desmethylclobazam (metabolite of clobazam)
-Flunitrazepam
-7-Aminoflunitrazepam (metabolite of flunitrazepam)
-Flurazepam
-2-Hydroxy ethyl flurazepam (metabolite of flurazepam)
-Lorazepam
-Prazepam
-Triazolam
-Alpha-hydroxy triazolam (metabolite of triazolam)
-Zolpidem
-Zolpidem phenyl-4-carboxylic acid (metabolite of zolpidem)
The clearance half-life of long-acting benzodiazepines is more than 24 hours. It takes 5 to 7 half-lives to clear 98% of a drug dose. Therefore, the presence of a long-acting benzodiazepine greater than the limit of quantification indicates exposure within a 5 to 20-day interval preceding specimen collection. Following a dose of diazepam, the drug and its metabolites appear in the urine within 30 minutes. Peak urine output is reached between 1 and 8 hours.
For additional information, including metabolism, clearance (half-life), and approximate detection times, see Optimize Urine Drug Monitoring for CNS Depressants.
Cautions
Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances
No significant cautionary statements
Clinical Reference
Recommendations for in-depth reading of a clinical nature
1. Gudin JA, Mogali S, Jones JD, Comer SD. Risks, management, and monitoring of combination of opioid, benzodiazepines, and/or alcohol use. Postgrad Med. 2013;125(4):115-130. doi:10.3810/pgm.2013.07.2684
2. Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC Clinical Practice Guideline for Prescribing Opioids for Pain-United States. MMWR Recomm Rep. 2022;71(No. RR-3):1-95
3. Baselt RC. Disposition of Toxic Drugs and Chemical in Man. 12th ed. Biomedical Publications; 2020
4. Langman LJ, Bechtel LK, Holstege CP. Clinical toxicology. In: Rifai N, Chiu RWK, Young I, Burnham CAD, Wittwer CT, eds. Tietz Textbook of Laboratory Medicine. 7th ed. Elsevier; 2023:chap 43
Method Description
Describes how the test is performed and provides a method-specific reference
Benzodiazepines are extensively metabolized by the liver and subsequently exist in the urine primarily as conjugated esters (-glucuronides). The conjugated metabolites are cleaved during a mild hydrolysis utilizing the enzyme glucuronidase. Stable isotope forms of the compounds are added as internal standards to account for extraction losses. An aliquot of the hydrolyzed sample is diluted, and the analytes are separated by liquid chromatography tandem mass spectroscopy and analyzed by multiple reaction monitoring.(Unpublished Mayo method)
PDF Report
Indicates whether the report includes an additional document with charts, images or other enriched information
Day(s) Performed
Outlines the days the test is performed. This field reflects the day that the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time before the test is performed. Some tests are listed as continuously performed, which means that assays are performed multiple times during the day.
Monday through Friday
Report Available
The interval of time (receipt of sample at Mayo Clinic Laboratories to results available) taking into account standard setup days and weekends. The first day is the time that it typically takes for a result to be available. The last day is the time it might take, accounting for any necessary repeated testing.
Specimen Retention Time
Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded
Performing Laboratory Location
Indicates the location of the laboratory that performs the test
Fees :
Several factors determine the fee charged to perform a test. Contact your U.S. or International Regional Manager for information about establishing a fee schedule or to learn more about resources to optimize test selection.
- Authorized users can sign in to Test Prices for detailed fee information.
- Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact Customer Service.
Test Classification
Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR) product.
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.
CPT Code Information
Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Clinic Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.
CPT codes are provided by the performing laboratory.
CPT codes are provided by the performing laboratory.
G0480
80347
80339
80368
LOINC® Information
Provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the order and results codes of this test. LOINC values are provided by the performing laboratory.
Test Id | Test Order Name | Order LOINC Value |
---|---|---|
BNZU | Benzodiazepines Confirmation, U | 90890-5 |
Result Id | Test Result Name |
Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
|
---|---|---|
608256 | Alprazolam by LC-MS/MS | 59615-5 |
608257 | Alpha-Hydroxyalprazolam by LC-MS/MS | 16348-5 |
608258 | Chlordiazepoxide by LC-MS/MS | 20522-9 |
608259 | Clonazepam by LC-MS/MS | 16229-7 |
608260 | 7-aminoclonazepam by LC-MS/MS | 51776-3 |
608261 | Diazepam by LC-MS/MS | 16227-1 |
608262 | Nordiazepam by LC-MS/MS | 16228-9 |
608263 | Midazolam by LC-MS/MS | 16233-9 |
608264 | Alpha-Hydroxy Midazolam by LC-MS/MS | 59590-0 |
608265 | Oxazepam by LC-MS/MS | 16201-6 |
608266 | Temazepam by LC-MS/MS | 20559-1 |
608267 | Clobazam by LC-MS/MS | 59635-3 |
608268 | N-Desmethylclobazam by LC-MS/MS | 97160-6 |
608269 | Flunitrazepam by LC-MS/MS | 20528-6 |
608270 | 7-aminoflunitrazepam by LC-MS/MS | 51777-1 |
608271 | Flurazepam by LC-MS/MS | 16231-3 |
608272 | 2-Hydroxy Ethyl Flurazepam by LC-MS/MS | 97159-8 |
608273 | Lorazepam by LC-MS/MS | 17088-6 |
608274 | Prazepam by LC-MS/MS | 17479-7 |
608275 | Triazolam by LC-MS/MS | 16232-1 |
608276 | Alpha-Hydroxy Triazolam by LC-MS/MS | 49876-6 |
608277 | Zolpidem by LC-MS/MS | 72770-1 |
608278 | Zolpidem Phenyl-4-Carboxylic acid by LC-MS/MS | 72768-5 |
608448 | Benzodiazepines Interpretation | 69050-3 |